Study finds Sodium Thiosulfate reduces Doxorubicin (DOX)-induced DNA damage
Doxorubicin (DOX), commonly used to treat a variety of cancers, has a number of adverse side effects including acute cardiotoxicity. DOX-induced cardiac dysfunction is due to reactive oxygen species (ROS)-mediated oxidative stress and subsequent apoptosis of cardiomyocytes. Methods to reduce the toxic effects of DOX are needed to improve the outcome of DOX-based chemotherapy.
A recent study by Mizuta et.al. from Kyushu University investigated the antioxidant, antiapoptotic, and cardioprotective effects of sodium thiosulfate (STS) in DOX-induced cardiomyopathy. STS is commonly used to treat cyanide poisoning and minor fungal infections, and it is considered among the safest medications on the World Health Organization’s list of essential medicines. The authors showed increases in oxidative stress markers in catalase and superoxide dismutase activity in animals treated with STS and lower levels of the DNA damage marker, 8-OHdG. This suggests that STS reduces DOX-induced DNA damage by improving antioxidant enzymes activities in cardiomyocytes. Catalase activity was measured using Arbor Assays’ kit, K033-H1, and we also produce kits for measuring superoxide dismutase activity, K028-H1, and the levels of 8-OHdG, K059-H1/H5, in a variety of samples.
- Time to answer: Measure catalase activity in 45 minutes
- Validated: Validated for use in serum, plasma, cells, tissue, and RBCs
- Cited: Well-cited in a variety of publications across species
- Samples/Kit: Enough reagents for 89 samples in duplicate
- Sensitive: Measure as little as 0.052 U/mL
- Precise: Intra-assay precision: < 5.0%, inter-assay precision: < 12%
- Stable: Includes stable, 4˚C liquid reagents
- Developed and manufactured in Ann Arbor, Michigan
|VIEW ALL KITS|